Cas:38530-07-3 3-(furan-2-yl)-1H-pyridazin-6-one manufacturer & supplier

Chemical Name:3-(furan-2-yl)-1H-pyridazin-6-one

CAS.NO:38530-07-3

Synonyms:BB_SC-8216;3-(2-Furyl)-6-(1H)-pyridazinon;6-(furan-2-yl)pyridazin-3-ol;6-furan-2-yl-2H-pyridazin-3-one;6-(2-Furyl)-3(2H)-pyridazinone;6-(2-furyl)pyridazin-3-ol;6-(furan-2-yl)-2,3-dihydropyridazin-3-one;F1967-0354

Molecular Formula:C₈H₆N₂O₂

Molecular Weight:162.14500

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:58.89000

Exact Mass:162.04300

LogP:1.02990

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like BB_SC-8216 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,F1967-0354 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-(furan-2-yl)-2,3-dihydropyridazin-3-one Use and application,F1967-0354 technical grade,usp/ep/jp grade.

Related News: The plant will complement Recipharm’s existing sites in France, Germany and Italy and will be focused on securing approvals from regulators in Europe and the U.S. (1S,4r)-N-(2-hydroxyethyl)-4-((9-((S)-tetrahydrofuran-3-yl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)cyclohexane-1-carboxamide manufacturers The company will see an immediate $6 billion bump to its topline thanks to Alexion’s C5 inhibitors, used to treat rare diseases like paroxysmal nocturnal hemoglobinuria. (N-Phenylbenzamido)(phenyl(trimethylsilyl)methylen)phosphan suppliers The green light converts the companies’ accelerated approval to a full approval for endometrial cancer that’s not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and for patients whose tumors have progressed following prior treatment. N2,N5-bis(5-((5-((3-(dimethylamino)propyl)carbamoyl)-1-methyl-1H-pyrrol-3-yl)carbamoyl)-1-methyl-1H-pyrrol-3-yl)-1H-indole-2,5-dicarboxamide vendor & factory The green light converts the companies’ accelerated approval to a full approval for endometrial cancer that’s not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and for patients whose tumors have progressed following prior treatment.,The plant will complement Recipharm’s existing sites in France, Germany and Italy and will be focused on securing approvals from regulators in Europe and the U.S.